Earnings Report·April 30, 2026
Bio-Rad Laboratories (NYSE: BIO) Advances 1.81% on Q1 Earnings Report
BIO rose to $280.12 following Q1 2026 results, with the in vitro diagnostics specialist posting solid profitability metrics.
Bio-Rad Laboratories Inc. (NYSE: BIO) Stock News & Analysis
Bio-Rad Laboratories Inc. (NYSE: BIO) is a healthcare company, listed on the NYSE. Alpha Stocks Insight tracks BIO across all major catalysts: quarterly earnings reports, analyst upgrades and downgrades, mergers and acquisitions, regulatory decisions, and significant price moves driven by sector or macro developments. This page centralises 2 articles published since April 30, 2026, providing investors with timely, data-driven analysis of Bio-Rad Laboratories Inc.'s financial performance and competitive position. New coverage is added each trading day.
BIO Coverage -- 2 Articles
Health Care·May 18, 2026
Elliott Management Identifies 'Hidden Billions' in Bio-Rad Laboratories Valuation
Activist investor Elliott sees significant hidden value in Bio-Rad Laboratories, citing operational and strategic potential that markets may be underpricing.
3 min readRead article
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.